Why Your Morning GH Test Lies (And the 7 Numbers That Don't)

Your morning GH blood test came back at 3.2 ng/mL. The lab flagged it as normal. You have been on ipamorelin for six weeks and expected something to show. Now you are staring at a number that tells you nothing. Here is why: you ordered the wrong test.

Growth hormone is not a flat, continuous signal. It fires in concentrated bursts, 6 to 12 times daily, with the largest pulse arriving 60 to 90 minutes after you fall asleep. Once that pulse fires, GH clears your bloodstream in 20 to 30 minutes. A morning blood draw almost always catches the interpulse valley, not the peak. The reading that comes back looks low. The lab does not flag it. You have no idea whether the protocol is working.

This article is the guide nobody sent you before your first draw. It covers what to test instead, what realistic peptide bloodwork actually looks like, and how your genes change what every number means.

Why a Random Serum GH Is the Wrong Test for Peptide Users

The 2019 Endocrine Society Clinical Practice Guideline in the Journal of Clinical Endocrinology and Metabolism addressed this directly. A single random serum GH, it states, is not useful for diagnosis of either GH deficiency or excess in most clinical contexts. This is not a recent discovery. Endocrinologists have known it for decades. The test is still offered by labs because it has other uses, not because it answers the question you are asking.

"A single random serum GH is not useful for diagnosis of either GH deficiency or excess in most clinical contexts outside of active acromegaly screening."

Molitch ME et al., Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism, 2019

The problem compounds for peptide users specifically. You are not GH-deficient. You are using secretagogues, which work by amplifying your natural pulses rather than replacing them. The result is more GH fired in bigger bursts, but still pulsatile. Your interpulse trough still reads near zero. Morning serum GH on ipamorelin looks almost identical to morning serum GH without ipamorelin. The difference happens at night, in the pulse, and it is gone by the time you arrive at the lab.

The Growth Hormone Research Society's 2022 consensus statement in the European Journal of Endocrinology reinforced the same point for adult GHD monitoring: the recommended biochemical marker is IGF-1, not serum GH, precisely because of this pulsatility problem. If the clinical standard for GH-deficient patients on prescription therapy is IGF-1, it is certainly the right starting point for a healthy person on a GH secretagogue stack.

The 7 Numbers That Tell You Whether Your Protocol Is Working

1. Age-Adjusted IGF-1 SDS (Not Raw ng/mL)

IGF-1 is produced by the liver in direct proportion to your cumulative GH exposure over the past 24 hours. It does not pulse. It does not clear in 30 minutes. It gives you a stable, integrated picture of what your GH axis did overnight. This is the right primary marker for GH peptide monitoring.

The catch is that raw ng/mL tells you almost nothing by itself. A 42-year-old with IGF-1 at 155 ng/mL is "normal" by the lab flag. In the age-specific reference range for competitive recreational athletes, that reading may sit in the 30th percentile. Normal is not optimal, and the reference range on your printout will not tell you that. What you want is IGF-1 expressed as a standard deviation score (SDS) against an age- and sex-matched reference population. The AACE/ACE Guidelines for Management of GH Deficiency in Adults, published in Endocrine Practice in 2020, specify SDS as the primary clinical anchor for monitoring, not raw ng/mL.

On a pulsatile secretagogue like ipamorelin, the typical IGF-1 response is a rise of 25 to 60 ng/mL from your baseline after 6 to 8 weeks of consistent dosing. That is not a dramatic number. If your baseline was 130 ng/mL, a working protocol looks like 155 to 185 ng/mL. Still within lab normal. Still not flagged. The peptide is doing its job. The expectation was calibrated to exogenous GH, which can push IGF-1 to 300 ng/mL and above. Secretagogues work differently, and the bloodwork reflects that.

2. IGFBP-3 (The Binding Protein Nobody Orders)

Insulin-Like Growth Factor Binding Protein 3 holds roughly 80 percent of your circulating IGF-1 in an inactive, bound form. The remaining 20 percent is the free IGF-1 fraction that actually reaches your tissues and drives downstream signaling. If your IGFBP-3 is low, because of insulin resistance, liver stress, or a genetic variant that suppresses its baseline expression, your effective free IGF-1 runs higher than your total IGF-1 suggests. Testing only total IGF-1 is reading the tank without knowing how much is flowing through the valve.

IGFBP-3 is not standard in most self-directed peptide monitoring panels. Most competitor articles on bloodwork do not mention it. Most compounding clinic intake forms do not require it. But adding it costs almost nothing, and it fundamentally changes how you interpret your IGF-1 number. Order both, every time.

3. The IGF-1:IGFBP-3 Molar Ratio

Once you have both numbers, calculate the ratio: molar IGF-1 divided by molar IGFBP-3. This is the signal that captures your free IGF-1 exposure at the tissue level. A 2023 study by Haj-Ahmad et al. in the Journal of Clinical Endocrinology and Metabolism tested the diagnostic performance of this ratio against individual markers. The result: the molar ratio achieved 87.5 percent sensitivity for GH deficiency detection. IGF-1 alone achieved 42.2 percent.

For a peptide user, a rising ratio with a rising total IGF-1 is a healthy sign that the GH signal is translating into tissue-available hormone. A rising ratio with stable IGF-1 points to a drop in IGFBP-3, which might reflect improving insulin sensitivity or early liver stress depending on context. An elevated ratio alongside IGF-1 above your age-adjusted upper range is the earliest warning sign of overexposure, before symptoms like joint swelling or fluid retention appear. Read the full breakdown of the IGF-1:IGFBP-3 ratio for interpretation cut-offs.

4. Fasting Glucose

GH is counter-regulatory to insulin. It stimulates lipolysis, raises free fatty acids, and can blunt insulin sensitivity in peripheral tissues. This is a documented effect of both exogenous GH and GH secretagogues, more pronounced at higher doses and more pronounced with MK-677 (which raises IGF-1 more aggressively over a longer period) than with pulsatile stacks like ipamorelin plus CJC-1295. Baseline fasting glucose before starting, then at weeks 6 and 12, gives you the earliest signal if your glucose metabolism is drifting.

A fasting glucose rising from 88 to 102 mg/dL over an 8-week protocol is not an emergency, but it is information. It is the difference between adjusting your carbohydrate timing and ignoring a trend that may compound over 6 to 12 months of continuous use.

5. Fasting Insulin

Fasting insulin is a more sensitive early signal than fasting glucose for metabolic stress from GH protocols. Glucose can stay normal for months while insulin is quietly climbing to compensate. A HOMA-IR score above 2.0 (calculated from fasting glucose and fasting insulin) points to insulin resistance developing before your glucose moves out of range. Most users who notice glucose effects from GH peptides could have caught the trend 4 to 8 weeks earlier with fasting insulin.

This is particularly relevant if your DNA flags metabolic risk. The effect is not universal, and it is dose-dependent. But it is real, it is documented, and it is easy to catch with one additional lab marker.

6. Your Baseline IGF-1 (Taken Before Week One)

This is the most common mistake in self-directed GH peptide monitoring: starting the protocol without a pre-protocol baseline. Without knowing where you started, a 170 ng/mL IGF-1 after 8 weeks of ipamorelin could mean your level rose 40 points (a clear response) or dropped 10 points (a possible problem). The number alone tells you nothing. The delta from baseline is the only metric that confirms whether the peptide is doing anything at all.

Test before week one. Test again at weeks 6 to 8. Compare both at the same time of day, under the same fasting conditions, using the same lab if possible. That comparison is your actual data. See the full guide to timing your IGF-1 draw for how to control for the variables that shift results between draws.

7. A Post-Dose GH Curve (For Protocol Confirmation)

If your IGF-1 delta is flat after 6 to 8 weeks on a pulsatile secretagogue at a confirmed dose, you have a few possibilities: the compound is not real, the timing is wrong, your receptor biology is blocking the response, or you are simply in the non-responder range for that specific peptide. A post-dose GH curve separates these cases. Draw blood at 0 minutes (pre-injection), 60 minutes, and 120 minutes after your normal dose. A working ipamorelin injection should produce a detectable GH peak at 60 to 90 minutes, typically 5 to 20 ng/mL above baseline depending on dose and individual sensitivity.

This is an optional advanced step, not a standard monitoring requirement. But if you have a flat IGF-1 delta and want to know why, it is the direct pharmacodynamic answer. It confirms whether the peptide is triggering GH pulses at all before you change dose, compound, or timing. For a complete picture of what your protocol bloodwork should look like, see how to read your peptide bloodwork.

The Reference Panel at a Glance

What Realistic Results Look Like on a GH Secretagogue Protocol

The most common source of confusion in GH peptide communities is that people calibrate their expectations to exogenous human growth hormone, not to secretagogues. Prescribed GH (somatropin) can push IGF-1 from 130 ng/mL to over 300 ng/mL in 12 weeks. That is not what ipamorelin, CJC-1295, or sermorelin do. These compounds amplify your existing pulses. They do not add a pharmaceutical GH signal on top of your biology.

A realistic 6 to 8 week ipamorelin plus CJC-1295 protocol at standard dosing looks like: IGF-1 rises 30 to 50 ng/mL from your personal baseline. IGFBP-3 rises slightly or holds flat. Fasting glucose is stable. You sleep better. You recover faster. You may notice changes in body composition at 10 to 16 weeks if other variables (training, protein intake, sleep quality) are consistent. The bloodwork will not look impressive by pharmaceutical GH standards. The peptide is still working.

If you see nothing after 8 weeks, including no shift in IGF-1 delta, that is the time to investigate. Check your compound source. Check your reconstitution and storage. Check your timing against the research on how GH pulses are affected by meal timing. Run a post-dose GH curve if needed. Rule out GHSR non-response before assuming the compound is faulty.

How Your Genetics Change What Every Number Means

Standard lab reference ranges were built from a reference population. They did not genotype that population. Two people with IGF-1 at 185 ng/mL can have meaningfully different underlying GH biology depending on which variant of the growth hormone receptor gene they carry. The d3 isoform of the GH receptor converts each GH pulse to IGF-1 more efficiently than the full-length version. Carriers of two d3 copies generate a higher IGF-1 response per unit of GH fired. Their "normal" sits higher. A standard dose of ipamorelin may push them toward the upper limit of the age-adjusted range before they or their prescriber expects it.

The IGFBP-3 angle is equally important. A genetic variant in the IGFBP-3 gene promoter reduces baseline IGFBP-3 expression by roughly 10 to 15 percent in carriers. If you carry this variant, your total IGF-1 understates your free IGF-1 exposure. The ratio will trend higher at any given IGF-1 level. You are not overexposed in a dangerous sense, but interpreting your raw IGF-1 as your tissue-level exposure is inaccurate. A 2021 review in Growth Hormone and IGF Research found that interpreting IGF-1 without accounting for GHR genotype produces systematic misclassification in up to 25 percent of individuals with relevant variants. Your genetics report can tell you which category you fall into. If you have not uploaded your raw data, start here, or order a saliva kit if you have not been tested.

None of this means your bloodwork is useless. It means you need to read it in context. IGF-1 plus IGFBP-3 plus your baseline delta plus your genotype gives you the full picture. Morning serum GH gives you a lucky guess.